Education
About Us
Working with TipRanks
Follow Us
Northwest Biotherapeutics (NWBO)
OTHER OTC:NWBO
NWBO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.17 - $0.48
Previous CloseN/A
Volume1.45M
Average Volume (3M)2.04M
Market Cap
$351.38M
Enterprise Value$136.14M
Total Cash (Recent Filing)$2.78M
Total Debt (Recent Filing)$69.00M
Price to Earnings (P/E)―
Beta0.68
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding1,457,994,100
10 Day Avg. Volume1,934,371
30 Day Avg. Volume2,043,564
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-6.22
Price to Sales (P/S)0.00
P/FCF Ratio-14.31
Enterprise Value/Market Cap0.39
Enterprise Value/Revenue22.33
Enterprise Value/Gross Profit92.42
Enterprise Value/Ebitda-0.49
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Northwest Biotherapeutics News
PremiumCompany Announcements
Northwest Biotherapeutics Addresses Market Rumor Concerns
PremiumCompany Announcements
Northwest Biotherapeutics Appoints Pat Sarma as Class II Director
PremiumCompany Announcements
Northwest Biotherapeutics Board Veteran Jasinowski Retires
Options Prices
Currently, No data available
---
Ownership Overview
NWBO FAQ
What was Northwest Biotherapeutics’s price range in the past 12 months?
Northwest Biotherapeutics lowest stock price was $0.17 and its highest was $0.48 in the past 12 months.
What is Northwest Biotherapeutics’s market cap?
Northwest Biotherapeutics’s market cap is $351.38M.
When is Northwest Biotherapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Northwest Biotherapeutics’s earnings last quarter?
Northwest Biotherapeutics released its earnings results on May 16, 2018. The company reported -$0.089 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.089.
Is Northwest Biotherapeutics overvalued?
According to Wall Street analysts Northwest Biotherapeutics’s price is currently Overvalued.
Does Northwest Biotherapeutics pay dividends?
Northwest Biotherapeutics does not currently pay dividends.
What is Northwest Biotherapeutics’s EPS estimate?
Northwest Biotherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Northwest Biotherapeutics have?
Northwest Biotherapeutics has 1,457,994,100 shares outstanding.
What happened to Northwest Biotherapeutics’s price movement after its last earnings report?
Northwest Biotherapeutics reported an EPS of -$0.089 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Northwest Biotherapeutics?
Currently, no hedge funds are holding shares in NWBO
Northwest Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
NWBO Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.68%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.71%
Trailing 12-Months
Company Description
Northwest Biotherapeutics
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
Technical Analysis
Altimmune
―
Checkpoint Therapeutics
―
Phathom Pharmaceuticals
―
Tourmaline Bio
―
Rapport Therapeutics, Inc.
―